ABSTRACT
This paper reviews some basic principles of Quantum Mechanics, Quantum Computing, and Artificial Intelligence in terms of a specific unifying theme. This theme relates to the hyperbolic or split-complex imaginary numbers and their equivalent matrices, rediscovered by Dirac, and the underlying mathematics of the previously described Q-UEL language based on them. Hyperbolic imaginary numbers h have the property hh = +1: contrast the more familiar i such that ii = -1. Examples of analogous matrices include that for the Hadamard gate as used in quantum computing and the Pauli spin matrices, and all Hermitian matrices of interest in quantum computing can readily be derived from these. They also relate to Dirac dualization, spinor projectors of Quantum Field Theory, the non-wave-like part of quantum theory, collapse of the wave function, and a dualized form of classical probability theory that has advantages in automated reasoning for medicine.
ABSTRACT
Editor's note: This article is one of an ongoing series covering topics published in conjunction with the Health Information Management and Systems Society (HIMSS) describing the development of blockchain technology and its applicability to healthcare.
ABSTRACT
BACKGROUND: The Depression Substudy of the Shingles Prevention Study (SPS) was designed to evaluate the association between major depression and immune responses to a high-titer live attenuated varicella zoster virus (VZV) vaccine (zoster vaccine), which boosts cell-mediated immunity (CMI) to VZV and decreases the incidence and severity of herpes zoster (HZ). The Depression Substudy was a 2-year longitudinal cohort study in 92 community-dwelling adults≥60 years of age who were enrolled in the SPS, a large, double-blind, placebo-controlled Veterans Affairs Cooperative zoster vaccine efficacy study. METHODS: Forty subjects with major depressive disorder, stratified by use of antidepressant medications, and 52 age- and sex-matched controls with no history of depression or other mental illness had their VZV-CMI measured prior to vaccination with zoster vaccine or placebo and at 6 weeks, 1 year, and 2 years postvaccination. RESULTS: Depressed subjects who were not treated with antidepressant medications had lower levels of VZV-CMI following administration of zoster vaccine than nondepressed controls or depressed subjects receiving antidepressants even when antidepressant medications failed to alter depressive symptom severity (P<.005). Similar results were obtained taking into account the time-varying status of depression and use of antidepressant medications, as well as changes in depressive symptoms, during the postvaccination period. CONCLUSIONS: Depressed patients have diminished VZV-CMI responses to zoster vaccine, and treatment with antidepressant medication is associated with normalization of these responses. Because higher levels of VZV-CMI correlate with lower risk and severity of HZ, untreated depression may increase the risk and severity of HZ and reduce the efficacy of zoster vaccine.
Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/immunology , Herpes Zoster Vaccine/immunology , Herpes Zoster/prevention & control , Herpesvirus 3, Human/immunology , Aged , Case-Control Studies , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/virology , Female , Herpes Zoster/immunology , Humans , Immunity, Cellular/drug effects , Longitudinal Studies , Male , Middle Aged , VaccinationABSTRACT
Major depressive disorder has been associated with activation of inflammatory processes as well as with reductions in innate, adaptive and non-specific immune responses. The objective of this study was to evaluate the association between major depression and a disease-relevant immunologic response, namely varicella-zoster virus (VZV)-specific immunity, in elderly adults. A cross-sectional cohort study was conducted in 104 elderly community dwelling adults ≥ 60years of age who were enrolled in the depression substudy of the shingles prevention study, a double blind, placebo-controlled vaccine efficacy trial. Fifty-two subjects had a current major depressive disorder, and 52 age- and sex-matched controls had no history of depression or any mental illness. VZV-specific cell-mediated immunity (VZV-CMI) was measured by VZV responder cell frequency (VZV-RCF) and interferon-γ enzyme-linked immunospot (ELISPOT) assays, and antibody to VZV was measured by an enzyme-linked immunosorbent assay against affinity-purified VZV glycoproteins (gpELISA). VZV-CMI, measured by VZV-RCF, was significantly lower in the depressed group than in the controls (p<0.001), and VZV-RCF was inversely correlated with the severity of depressive symptoms in the depressed patients. In addition, an age-related reduction in VZV-RCF was observed in the depressed patients, but not in the controls. Furthermore, there was a trend for depressive symptom severity to be associated with lower ELISPOT counts. Finally, VZV-RCF was higher in depressed patients treated with antidepressant medications as compared to untreated depressed patients. Since lower levels of VZV-RCF appear to explain the increased risk and severity of herpes zoster observed in older adults, these findings suggest that, in addition to increasing age, depression may increase the risk and severity of herpes zoster.
Subject(s)
Aging/immunology , Antidepressive Agents/immunology , Depressive Disorder, Major/immunology , Herpes Zoster/immunology , Herpesvirus 3, Human/immunology , Immunity, Cellular/immunology , Aged , Aged, 80 and over , Aging/blood , Analysis of Variance , Antibodies, Viral/blood , Antidepressive Agents/therapeutic use , Case-Control Studies , Cohort Studies , Cross-Sectional Studies , Depressive Disorder, Major/blood , Depressive Disorder, Major/drug therapy , Female , Herpes Zoster/psychology , Humans , Immunity, Cellular/drug effects , Male , Matched-Pair Analysis , Middle Aged , Reference Values , Risk FactorsABSTRACT
This study sought to identify mechanisms behind resistance to third-generation cephalosporins and ciprofloxacin in Irish multidrug-resistant Enterobacteriaceae isolates. The most prevalent extended-spectrum beta-lactamase genes identified were bla SHV-12 and bla CTX-M-15. These were associated with the fluoroquinolone resistance genes aac(6')-IB-cr, qnrA and qnrB, not previously reported in Irish isolates.
Subject(s)
Bacterial Proteins/genetics , Drug Resistance, Multiple, Bacterial , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/drug effects , Genes, Bacterial , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Ciprofloxacin/pharmacology , Enterobacteriaceae/enzymology , Enterobacteriaceae/genetics , Enterobacteriaceae/isolation & purification , Genotype , Humans , Ireland/epidemiology , Microbial Sensitivity Tests , PrevalenceABSTRACT
BACKGROUND: The urea breath test (UBT) is the gold-standard non-invasive test for the detection of Helicobacter pylori infection, however, the lack of availability of the UBT due to the high cost of the test, and in particular the need for expensive analytical instrumentation, limits the usefulness of this method. Stool antigen assays may offer an alternative non-invasive method for the diagnosis of infection. OBJECTIVE: To compare the accuracy of three stool antigen assays (HpSA, IDEIA HpStAR, and ImmunoCard STAT) against the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome. METHODS: A total of 102 patients attending two gastroenterology day-case clinics for the investigation of dyspepsia were included. Each patient provided breath and stool samples for analysis. Patients who tested positive for H. pylori by the validated UBT were prescribed triple therapy and invited to return for repeat breath and stool sample analysis 6 weeks post-treatment. RESULTS: Of the 102 patients tested, 48 were diagnosed with H. pylori infection by the UBT. The HpSA assay interpreted 38 of these as positive (79% sensitive). Of the 54 UBT-negative patients the HpSA assay interpreted all 54 as negative (100% specific). The IDEIA HpStAR assay correctly identified 44 patients as positive (92% sensitive) and 50 as negative (92.5% specific). The ImmunoCard STAT assay interpreted 38 patients as positive (79% sensitive) and 52 as negative (96.3% specific). CONCLUSION: The findings indicate that the IDEIA HpStAR stool antigen kit is the most accurate assay of the three assays evaluated, and possibly represents a viable alternative to the UBT for the primary diagnosis of H. pylori infection and for monitoring treatment outcome.